Tharimmune Stock Today
| THAR Stock | 2.26 0.04 1.74% |
Performance0 of 100
| Odds Of DistressOver 85
|
Tharimmune is selling at 2.26 as of the 28th of November 2024; that is 1.74% down since the beginning of the trading day. The stock's lowest day price was 2.26. Tharimmune has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Tharimmune are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of January 2022 | Category Healthcare | Classification Health Care |
Tharimmune is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 1.49 M outstanding shares of which 496.87 K shares are at this time shorted by private and institutional investors with about 0.04 trading days to cover. More on Tharimmune
Moving together with Tharimmune Stock
Moving against Tharimmune Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tharimmune Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman President | Randy MBA | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Tharimmune can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tharimmune's financial leverage. It provides some insight into what part of Tharimmune's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Tharimmune (THAR) is traded on NASDAQ Exchange in USA. It is located in 1200 Route 22 East, Bridgewater, NJ, United States, 08807 and employs 2 people. Tharimmune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.42 M. Tharimmune conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.49 M outstanding shares of which 496.87 K shares are at this time shorted by private and institutional investors with about 0.04 trading days to cover.
Tharimmune generates negative cash flow from operations
Check Tharimmune Probability Of Bankruptcy
Ownership AllocationAbout 96.57 % of Tharimmune outstanding shares are held by general public with 1.79 (%) owned by insiders and only 1.63 % by institutional holders.
Check Tharimmune Ownership Details
Tharimmune Historical Income Statement
Tharimmune Stock Against Markets
Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.